On October 9, 2026, a clinical trial listing was updated showing a Phase 1 study titled "Acute Effects of Intravenous 5-MeO-DMT in Healthy Participants" as recruiting. The trial is registered under identifier NCT07444788 on ClinicalTrials.gov. According to the listing, the study status is currently marked RECRUITING and the trial phase is listed as Phase 1. No results have been posted for this trial at this time. The event data provided does not include information on study endpoints, participant criteria, or enrollment numbers beyond the recruiting status. No efficacy or safety outcomes are included in this update, and none should be inferred. This brief reports only the status and phase information as listed in the trial registry entry. Readers interested in background information on oxytocin, including its approved regulatory status, can consult the compound overview for additional context.
Oxytocin-Linked Trial NCT07444788 Recruiting for Phase 1 Study
See the full oxytocin overview
Source: https://clinicaltrials.gov/study/NCT07444788